Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CALTX.ST
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Calliditas Therapeutics AB (publ) stock downgraded to Hold/Accumulate
(Updated on May 10, 2024)

Buy or Hold candidate since May 07, 2024 Loss -0.89% PDF

The Calliditas Therapeutics AB (publ) stock price fell by -1.07% on the last day (Friday, 10th May 2024) from kr112.00 to kr110.80. During the last trading day the stock fluctuated 3.37% from a day low at kr109.80 to a day high of kr113.50. The price has risen in 6 of the last 10 days and is up by 10.36% over the past 2 weeks. Volume has increased on the last day by 31 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 108 thousand shares were bought and sold for approximately kr11.95 million.

The stock lies the upper part of a wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at kr111.91 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -4.36% during the next 3 months and, with a 90% probability hold a price between kr94.95 and kr107.03 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CALTX.ST Signals & Forecast

The Calliditas Therapeutics AB (publ) stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at kr109.56 and kr108.62. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, May 08, 2024, and so far it has fallen -1.07%. Further fall is indicated until a new bottom pivot has been found. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Calliditas Therapeutics AB (publ) stock

Calliditas Therapeutics AB (publ) finds support from accumulated volume at kr108.30 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved kr3.70 between high and low, or 3.37%. For the last week, the stock has had daily average volatility of 3.58%.

Our recommended stop-loss: kr107.47 (-3.01%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 1 day ago.)

Trading Expectations (CALTX.ST) For The Upcoming Trading Day Of Monday 13th

For the upcoming trading day on Monday, 13th we expect Calliditas Therapeutics AB (publ) to open at kr111.37, and during the day (based on 14 day Average True Range), to move between kr106.70 and kr114.90, which gives a possible trading interval of +/-kr4.10 (+/-3.70%) up or down from last closing price. If Calliditas Therapeutics AB (publ) takes out the full calculated possible swing range there will be an estimated 7.41% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at kr111.80 (0.90%) than the support at kr108.30 (2.26%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Calliditas Therapeutics AB (publ) stock A Buy?

Calliditas Therapeutics AB (publ) holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold/Accumulate candidate.

Current score: 0.086 Hold/Accumulate Downgraded

Predicted Opening Price for Calliditas Therapeutics AB (publ) of Monday, May 13, 2024

Fair opening price May 13, 2024 Current price
kr111.37 ( 0.511%) kr110.80

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CALTX.ST

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 115.07 3.85 %
R2 113.65 2.58 %
R1 112.78 1.79 %
Current price: 110.80
Support S1 109.95 -0.764 %
S2 109.08 -1.55 %
S3 107.67 -2.83 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 115.20 3.97 %
R2 114.30 3.16 %
R1 111.80 0.90 %
Current price 110.80
Support S1 108.30 -2.26%
S2 108.20 -2.35%
S3 106.90 -3.52%

FAQ

What is the symbol for Calliditas Therapeutics AB (publ) Stock and on which exchange is it traded?
The symbol for Calliditas Therapeutics AB (publ) is CALTX.ST and it is traded on the OMX (Stockholm Stock Exchange).

Should I buy or sell Calliditas Therapeutics AB (publ) Stock?
Calliditas Therapeutics AB (publ) holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold/Accumulate candidate.

How to buy Calliditas Therapeutics AB (publ) Stock?
Calliditas Therapeutics AB (publ) Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Calliditas Therapeutics AB (publ) Stock.

What's the current price of Calliditas Therapeutics AB (publ) Stock?
As of the end of day on the May 10, 2024, the price of an Calliditas Therapeutics AB (publ) (CALTX.ST) share was kr110.80.

What is the 52-week high and low for Calliditas Therapeutics AB (publ) Stock?
The 52-week high for Calliditas Therapeutics AB (publ) Stock is kr141.90 and the 52-week low is kr80.80.

What is the market capitalization of Calliditas Therapeutics AB (publ) Stock?
As of the May 10, 2024, the market capitalization of Calliditas Therapeutics AB (publ) is 5.947B.

When is the next earnings date for Calliditas Therapeutics AB (publ)?
The upcoming earnings date for Calliditas Therapeutics AB (publ) is May 23, 2024.
Click to get the best stock tips daily for free!

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is S... CALTX.ST Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT